Alopecia affects millions of people around the world and does not discriminate against age, gender, and ethnicity. Androgenic alopecia, male or female patterned baldness, is one of the most common types of alopecia; however, alopecia areata, totalis, and universalis also affect a large part of the population. In a recent post in anticipation of other clinical trials and studies, we pointed out these and a few hair loss trials. Now, we have one closer to home.
In collaboration with the Tennessee Clinical Research Center, we are supporting efforts to increase awareness of a local clinical research study currently looking for adults with alopecia areata (bald patches on the scalp), or with alopecia universalis–which can result in total loss of all scalp and body hair including eyebrows, eyelashes, and intranasal hair, or alopecia totalis (total scalp hair loss) to participate in a study of an oral investigational drug. Under the direction of Dr. Michael Gold, the trial focuses on oral medication, which have been shown to be more effective than topical treatments. Interested?
YOU MAY QUALIFY TO PARTICIPATE IF YOU:
- Are at least 18 years old
- Have areas of hair loss on the scalp due to Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT)
- Have been experiencing the current episode of AA, AU, or AT for at least 6 months and no more than 7 years
- Have 30-100% total scalp hair loss
- Are willing to stop any current prohibited treatments for your scalp hair loss
- Are willing to attend regular study visits involving lab tests, electrocardiograms, questionnaires, and other study procedures for the duration of the study
HPIHair is not an active participate nor conducting the trials. We support and believe in the science the trials employ. For more information, call April at the Tennessee Clinical Research Center 615.383.9660 ext. 175 or email email@example.com.
The Tennessee Clinical Research Center can be found at 2000 Richard Jones Road, Suite 223 Nashville, TN 37215 and online at www.tnclinicalresearch.com.